Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

Nature Reviews Neuroscience

Volumn 2, Issue 8, 2001, Pages 577-588

  Bezard, Erwan ^a,b   Brotchie, Jonathan M ^b,c   Gross, Christian E ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Williams House   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA;

ANIMAL; BASAL GANGLION; DISEASE MODEL; DRUG EFFECT; DYSKINESIA; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0035434121     PISSN: 14710048     EISSN: None     Source Type: Journal    
DOI: 10.1038/35086062     Document Type: Review

References (140)

1. Parkinson, J. An Essay on the Shaking Palsy (Sherwood, Neely & Jones, London, 1817).
2. Ehringer, H. & Homykiewicz, O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr. 38, 1236-1239 (1960).
3. Carlsson, A., Lindquist, M. & Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200 (1957).
4. Birkmayer, W. & Homykiewicz, O. Der L-Dioxyphenylalanin effekt bei der Parkinson-Akinese. Wien. Min. Wschr. 73, 787-788 (1961).
5. Fahn, S. 'On-off' phenomenon with levodopa therapy in parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 24, 431-441 (1974).
6. Duvoisin, R. C. Variations in the 'on-off' phenomenon. Adv. Neurol. 5, 339-340 (1974).
7. Marsden, C. D. & Parkes, J. D. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1, 292-296 (1976).
8. Marsden, C. D., Parkes, J. D. & Quinn, N. in Movement Disorders (eds Marsden, C. D. & Fahn, S.) 96-122 (Butterworth, London, 1982).
9. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinsons disease in DATATOP patients requiring levodopa. Ann. Neurol. 39, 37-45 (1996).
10. Quinn, N. Drug treatment of Parkinson's disease. Br. Med. J. 310, 575-579 (1995).
11. Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinsons disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 342, 1484-1491 (2000).
12. Alexander, G. E., DeLong, M. R. & Strick, P. L Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357-381 (1986).
13. Alexander, G. E & Crutcher, M. D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271 (1990).
14. DeLong, M. R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285 (1990).
15. Penney, J. B. & Young, A. B. Speculations on the functional anatomy of basal ganglia disorders. Annu. Rev. Neurosci. 6, 73-94 (1983).
16. Bezard, E., Crossman, A. R., Gross, C. E. & Brotchie, J. M. Structures outside the basal ganglia may compensate for dopamine loss in the pre-symptomatic stages of Parkinson's disease. FASEB J. 15, 1092-1094 (2001).
17. Rascol, O. et al. Supplementary and primary sensory motor area activity in Parkinson's disease: regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch. Neurol. 49, 144-148 (1992).
18. Crossman, A. R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia related involuntary movement disorders. Neuroscience 21, 1-40 (1987).
19. Crossman, A. R. A hypothesis on the pathophysiological mechanisms that underlie levodopa-or dopamine-agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 5, 100-108 (1990).
20. Cotzias, G. C., Papavasiliou, P. S. & Gellene, R. Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med. 280, 337-345 (1969).
21. Yahr, M. D., Duvoisin, R. C., Hoehn, M. M., Schear, M. J. & Barrett, R. E. L-Dopa: its clinical effects in parkinsonism. Trans. Am. Neurol. Assoc. 93, 56-63 (1968).
22. Melamed, E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch. Neurol. 36, 308-310 (1979).
23. Muenter, M. D., Sharpless, N. S., Tyce, G. M. & Darley, F. L Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy for Parkinson's disease. Mayo Clin. Proc. 52, 163-174 (1977).
24. Klawans, H. L., Goetz, C. & Bergen, D. Levodopa-induced myoclonus. Arch. Neurol. 32, 330-334 (1975).
25. Engber, T. M., Susel, Z., Juncos, J. L. & Chase, T. N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168, 291-298 (1989).
26. Cenci, M.A., Lee, C.S. & Bjorklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706 (1998).
27. Henry, B., Crossman, A. R. & Brotchie, J. M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155, 204-220 (1999).
28. Langston, J. W., Ballard, P. A., Tetrud, J. W. & Irwin, I. Chronic parkinsonism in human due to a product of meperidine analog synthesis. Science 219, 979-980 (1983).
29. Langston, J. W. & Ballard, P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11, 160-165 (1984).
30. Brotchie, J. M. & Fox, S. H. Quantitative assessment of dyskinesias in subhuman primates. Mov. Disord 14, 40-47 (1999).
31. Boraud, T., Bezard, E., Bioulac, B. & Gross, C. in The Basal Ganglia VI (ed. Graybiel, A.) (Kluwer Academic, Norwell, in the press).
32. Boraud, T., Bezard, E., Guehl, D., Bioulac, B. & Gross, C. Effects of L-DOPA on neuronal activity of the globus pallidus extemalis (GPe) and globus pallidus intemalis (GPi) in the MPTP-treated monkey. Brain Res. 787, 157-160 (1998).
33. Mitchell, I. J., Boyce, S., Sambrook, M. A. & Crossman, A. R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 115, 809-824 (1992).
34. Vila, M. et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA J. Neurosci. 17, 765-773 (1997).
35. Papa, S. M., Desimone, R., Fiorani, M. & Oldfield, E. H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann. Neurol. 46, 732-738 (1999).
36. Lozano, A. M., Lang, A. E., Levy, R., Hutchison, W. & Dostrovsky. J. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann. Neurol. 47, S141-146 (2000).
37. Filion, M., Tremblay, L. & Bedard, P. J. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547, 152-161 (1991).
38. Mitchell, I. J. et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32, 213-226 (1989).
39. Filion, M. Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. Brain Res. 547, 142-151 (1979).
40. Boraud, T., Bezard, E., Bioulac, B. & Gross, C. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alteration of pallidal neurons in the MPTP-treated monkey. Brain 124, 546-557 (2001).
41. Hutchinson, W. D., Levy, R., Dostrovsky, J. O., Lozano, A. M. & Lang, A. E. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. 42, 767-775 (1997).
42. Stefani, A. et al. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. J. Neural Transm. 104, 895-904 (1997).
43. Brooks, D. J., Piccini, P., Turjanski, N. & Samuel, M. Neuroimaging of dyskinesia. Ann. Neurol. 47, S154-159 (2000).
44. Rascol, O. et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 121, 527-533 (1998).
45. Lozano, A. M. & Lang, A. E. Pallidotomy for Parkinson's disease. Neurosurg. Clin. N. Am. 9, 325-336 (1998).
46. Ng, K. Y., Chase, T. N., Colburn, R. W. & Kopin, I. J. L-Dopa-induced release of cerebral monoamines. Science 170, 76-77 (1970).
47. Melamed, E., Hefti, F., Liebman, J., Schlosberg, A. J. & Wurtman, R. J. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature 283, 772-774 (1980).
48. Melamed, E., Hefti, F., Pettibone, D. J., Liebman, J. & Wurtman, R. J. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology 31, 651-655 (1981).
49. Lopez, A., Munoz, A., Guerra, M. J. & Labandeira-Garcia, J. L. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103, 639-651 (2001).
50. Nutt, J. G., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 23, 109-115 (2000).
51. Olanow, W., Schapira, A. H. & Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23, 117-126 (2000).
52. Colzi, A., Turner, K. & Lees, A. J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64, 573-576 (1998).
53. Quinn, N., Parkes, J. D. & Marsden, C. D. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34, 1131-1136 (1984).
54. Marion, M. H., Stocchi, F., Quinn, N. P., Jenner, P. & Marsden, C. D. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Clin. Neuropharmacol. 9, 165-181 (1986).
55. Olanow, C. W. & Obeso, J. A. Preventing levodopa-induced dyskinesias. Ann. Neurol. 47, 5167-178 (2000).
56. Feuerstein, C. et al. Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation. Acta Neurol. Scand. 56, 508-524 (1977).
57. Montgomery, E. B. Jr Pharmacokinetics and pharmacodynamics of levodopa. Neurology 42, 17-22 (1992).
58. Breier, A. et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl Acad. Sci. USA 94, 2569-2574 (1997).
59. Tedroff, J. et al. L-Dopa modulates striatal dopaminergic function in vivo: evidence from PET investigations in nonhuman primates. Synapse 25, 56-61 (1997).
60. 11C]raclopride displacement and PET. Neurology 46, 1430-1436 (1996).
61. De la Fuente-Femandez, R. et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 49, 298-303 (2001).
62. Lee, T., Seeman, P., Rajput, A., Farley, I. J. & Hornykiewicz, O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273, 150-151 (1978).
63. Creese, I., Burt, D. R. & Snyder, S. H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197, 596-598 (1977).
64. Graham, W.C., Sambrook, M.A. & Crossman, A.R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 602, 290-303 (1993).
65. Gerfen, C. R. et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432 (1990).
66. Shinotoh, H., Hirayarna, K. & Tateno, Y. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Adv. Neurol. 60, 488-493 (1993).
67. 11C-raclopride and positron emission tomography. Ann. Neurol. 31, 184-192 (1992).
68. Shinotoh, H. et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J. Neurol. Neurosurg. Psychiatry 56, 467-472 (1993).
69. Levey, A. I. et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl Acad. Sci. USA 90, 8861-8885 (1993).
70. Dumartin, B., Caillé, I., Gonon, F. & Bloch, B. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J. Neurosci. 18, 1650-1651 (1998).
71. Muriel, M. P. et al. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann. Neurol. 46, 103-111 (1999).
72. Walaas, S. I., Aswaad, S. W. & Greengard, P. A dopamine-and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301, 69-71 (1984).
73. Gerfen, C. R. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 23, S64-70 (1995).
74. Berke, J. D., Paletzki, R. F., Aronson, G. J., Hyman, S. E. & Gerfen, C. R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18, 5301-5310 (1998).
75. Gerfen, C. R., Keefe, K. A. & Gauda, E. B. D1 and D2 dopamine receptor function h the striatum: ccactivation of D1-and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene responses in D1-containing neurons. J. Neurosci. 15, 8167-8176 (1995).
76. Steiner, H. & Gerfen, C. R. Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: relative contributions of pre-and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene expression. J. Comp. Neurol. 376, 530-541 (1996).
77. Gomez-Mancilla, B. & Bedard, P. J. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 259, 409-413 (1991).
78. Pearce, R. K., Banerji, T., Jenner, P. & Marsden, C. D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 13, 234-241 (1998).
79. Rascol, O. Medical treatment of levodopa-induced dyskinesias. Ann. Neurol. 47, S179-183 (2000).
80. Aizman, O. et al. Anatomical and physiological evidence for D-1 and D-2 dopamine receptor colocalization in neostriatal neurons. Nature Neurosci. 3, 226-230 (2000).
81. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl Acad. Sci. USA 89, 8155-8159 (1992).
82. Sokoloff, P., Giros, B., Martres, M.-P. Bouthenet, M.-L. & Schwartz, J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146-151 (1990).
83. Levesque, D. et al. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl Acad. Sci. USA 92, 1719-1723 (1995).
84. Bordet, R. et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl Acad. Sci. USA 94, 3363-3367 (1997).
85. Pilla, M. et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400, 371-375 (1999).
86. Bordet, R., Ridray, S., Schwartz, J. C. & Sokoloff, P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-OHDA-lesioned rats. Eur. J. Neurosci. 12, 2117-2123 (2000).
87. Gross, C. E., Boraud, T., Guehl, D., Bioulac, B. & Bezard, E. From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research? Prog. Neurobiol. 56, 509-532 (1999).
88. Parent, A. & Hazrati, L-N. Functional anatomy of the basal ganglia I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20, 91-127 (1995).
89. Kotter, R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44, 163-196 (1994).
90. Calabresi, P., Pisani, A., Mercuri, N. B. & Bernardi, G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19, 19-24 (1996).
91. Calabresi, P., Pisani, A., Centonze, D. & Bernardi, G. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci. Biobehav. Rev. 21, 519-523 (1997).
92. Calabresi, P. et al. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61, 231-265 (2000).
93. Tang, K. C., Low, M. J., Grandy, D. K. & Lovinger, D. M. Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc. Natl Acad. Sci. USA 98, 1255-1260 (2001).
94. Dunah, A. W. et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57, 342-352 (2000).
95. Ganguly, A. & Keefe, K. A. Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience 103, 405-412 (2001).
96. Ingham, C.A., Hood, S.H., Maldegem, V.B., Weenink, A. & Arbuthnott, G. W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 93, 17-27 (1993).
97. Menegoz, M., Lau, L. F. Herve, D., Huganir, R. L. & Girault, J. A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OHDA lesions. Neuroreport 7, 125-128 (1995).
98. Del Fiacco, M., Paxinos, G. & Cuello, A. C. Neostriatal enkephalin-immunoreactive neurons project to the globus pallidus. Brain Res. 231, 1-17 (1982).
99. Maneuf, Y. P., Mitchell, I. J., Crossman, A. R. & Brotchie, J. M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125, 65-71 (1994).
100. 3H]-5HT from slices of rat globus pallidus. Biochem. Pharmacol. 36, 1738-1741 (1987).
101. Henry, B. & Brotchie, J. M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 9, 149-158 (1996).
102. Herrero, M. T. et al. Effects of L-dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 68, 1189-1198 (1995).
103. Morissette, M., Grondin, R., Goulet, M., Bedard, P. J. & Di Paolo, T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists. J. Neurochem. 72, 682-692 (1999).
104. Zeng, B. Y., Pearce, R. K. B., MacKenzie, G. M. & Jenner, P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur. J. Neurosci. 12, 1096-1104 (2000).
105. Mehta, A., Bot, G., Reisine, T. & Chesselet, M. F. Endomorphin-1: induction of motor behavior and lack of receptor desensitization. J. Neurosci. 21, 4436-4442 (2001).
106. Gerfen, C. R., McGinty, J. F. & Young, W. S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11, 1016-1031 (1991).
107. Engber, T. M., Susel, Z., Kuo, S., Gerfen, C. R. & Chase, T. N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552, 113-118 (1991).
108. Maneuf, Y. P., Mitchell, I. J., Crossman, A. R., Woodruff, G. N. & Brotchie, J. M. Functional implications of κ-opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683, 102-108 (1995).
109. Hill, M. P. Modulation of glutamate release by κ-opioid receptor agonist in rodent and primate striatum. Eur. J. Pharmacol. 281, R1-2 (1995).
110. Stoessl, A. J., Polanski, E. & Frydryszak, H. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. Mov. Disord. 8, 445-452 (1993).
111. Piccini, P., Weeks, R. A. & Brooks, D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42, 720-726 (1997).
112. Johansson, P. A., Andersson, M., Andersson, K. E. & Cenci, M. A. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 8, 220-239 (2001).
113. Brotchie, J. M. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. 13, 871-876 (1998).
114. Rascol, O. et al. Induction by dopamine D-1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol. 58, 249-254 (2001).
115. 3 dopamine receptor. 5° Colloque de la Société des Neurosciences 5, 14 (2001).
116. Dziewczapolski, G. et al. Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonudeotides. Neuroreport 9, 1-5 (1998).
117. Papa, S. M. & Chase, T. N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39, 574-578 (1996).
118. Blanchet, P. J., Konitsiotis, S. & Chase, T. N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13, 798-802 (1998).
119. Blanchet, P. J. et al. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290, 1034-1040 (1999).
120. Verhagen Metman, L. et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1326 (1998).
121. Luginger, E., Wenning, G. K., Bosch, S. & Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 15, 873-878 (2000).
122. Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E. & Chase, T. N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589-1595 (2000).
123. Trabucchi, M., Bassi, S. & Frattola, L Effect of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch. Neurol. 39, 120-121 (1982).
124. Sandyk, R. & Snider, S. R. Naloxone treatment of L-dopa-induced dyskinesias in Parkinsons disease. Am. J. Psychiatry 143, 118 (1986).
125. Manson, A. J., Katzenschlager, R., Hobart, J. & Lees, A. J. High dose naltrexone for dyskinesias induced by levodopa. J. Neurol. Neurosurg. Psychiatry 70, 554-556 (2001).
126. Nutt, J. G., Rosin, A. J., Eisler, T., Calne, D. B. & Chase, T. N. Effect of an opiate antagonist on movement disorders. Arch. Neurol. 35, 810-811 (1978).
127. Rascol, O. et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinsons disease. Mov. Disord. 9, 437-440 (1994).
128. Schiffmann, S. N., Jacobs, O. & Vanderhaeghen, J. J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57, 1062-1067 (1991).
129. Svenningsson, P. et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J. Comp. Neurol. 399, 229-240 (1998).
130. 2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20, 7782-7789 (2000).
131. Kanda, T. et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507-513 (1998).
132. Jenner, P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. 247, 43-50 (2000).
133. Brotchie, J. M. et al. Cannabinoid receptors and L-DOPA-induced dyskinesia in Parkinsons disease. Soc. Neurosci. Abstr. 24 (1998).
134. Fox, S. H., Hill, M. P., Crossman, A. R. & Brotchie, J. M. On the role of endocannabinoids in L-DOPA-induced dyskinesia. Soc. Neurosci. Abstr. 25, 1462 (1999).
135. 2-adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 1237-1246 (1999).
136. 2 antagonist in a 20-year-old java monkey with MPTP-induced parkinsonian signs. Brain Res. Bull. 26, 627-631 (1991).
137. 2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14, 744-753 (1999).
138. Gomez-Mancilla, B. & Bedard, P. J. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427 (1993).
139. 2-Adrenoceptor antagonists: a new approach to Parkinsons disease? CNS Drugs 10, 189-207 (1998).
140. 2-adrenoceptor antagonist idazoxan. Mov. Disord. (in the press).